VRNA News & Events

Soleno Therapeutics (SLNO) announced the appointment of biopharmaceutical finance veteran Mark Hahn as an independent director to its Board of Directors and a member of its Audit Committee. With the addition of Hahn, the Soleno Board increases to seven seats. Prior to joining the Soleno Board, Hahn served as Chief Financial Officer of Verona Pharma (VRNA)

Merck (MRK) announced the completion of the Verona Pharma (VRNA) acquisition. Verona Pharma is now a wholly-owned subsidiary of Merck and the American Depositary Shares of Verona Pharma will no longer be listed or traded on the Nasdaq Global Market.

Verona Pharma (VRNA), which entered into a definitive agreement on July 8 relating to its proposed acquisition by Merck (MRK) through a wholly owned subsidiary or a nominee, announced that the High Court of Justice of England and Wales has approved the proposal for Merck to acquire Verona Pharma for $107 per ADS, each of which represents eight Verona Pharma ordinary shares, for a total transaction value of approximately $10B. Closing of the transaction will occur and the scheme will become effective upon the court order being delivered to the Registrar of Companies, which is expected to occur on October 7, as previously announced.